Journal article
GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia
RS Mehta, SG Holtan, T Wang, MT Hemmer, SR Spellman, M Arora, DR Couriel, AM Alousi, J Pidala, H Abdel-Azim, I Ahmed, M Aljurf, M Askar, JJ Auletta, V Bhatt, C Bredeson, S Chhabra, S Gadalla, J Gajewski, RP Gale Show all
Blood Advances | AMER SOC HEMATOLOGY | Published : 2019
Open access
Abstract
We report graft-versus-host disease (GVHD)-free relapse-free survival (GRFS) (a composite end point of survival without grade III-IV acute GVHD [aGVHD], systemic therapy-requiring chronic GVHD [cGVHD], or relapse) and cGVHD-free relapse-free survival (CRFS) among pediatric patients with acute leukemia (n = 1613) who underwent transplantation with 1 antigen-mismatched (7/8) bone marrow (BM; n = 172) or umbilical cord blood (UCB; n = 1441). Multivariate analysis was performed using Cox proportional hazards models. To account for multiple testing, P < .01 for the donor/graft variable was considered statistically significant. Clinical characteristics were similar between UCB and 7/8 BM recipient..
View full abstractGrants
Awarded by National Cancer Institute
Funding Acknowledgements
The CIBMTR is supported primarily by Public Health Service Grant/Cooperative Agreement 5U24CA076518 from the National Institutes of Health, National Cancer Institute, National Heart, Lung, and Blood Institute, and National Institute of Allergy and Infectious Diseases; Grant/Cooperative Agreement 1U24HL138660 from the National Institutes of Health, National Heart, Lung, and Blood Institute and National Cancer Institute; contract HHSH250201700006C with the Health Resources and Services Administration/Department of Health and Human Services; and grants N00014-17-1-2388, N00014-171-2850, and N00014-18-1-2045 from the Office of Naval Research; and grants from Adaptive Biotechnologies; *Amgen, Inc.; anonymous donation to the Medical College of Wisconsin; Astellas Pharma US; Atara Biotherapeutics, Inc.; Be the Match Foundation; *bluebird bio, Inc.; *Bristol-Myers Squibb Oncology; *Celgene Corporation; *Chimerix, Inc.; *CytoSen Therapeutics, Inc.; Fred Hutchinson Cancer Research Center; Gamida Cell Ltd.; Gilead Sciences, Inc.; HistoGenetics, Inc.; Immucor; *Incyte Corporation; Janssen Scientific Affairs, LLC; *Jazz Pharmaceuticals, Inc.; Karius, Inc.; Karyopharm Therapeutics, Inc.; *Kite Pharma, Inc.; Medac, GmbH; Mediware; Medical College of Wisconsin; * Merck & Co., Inc.; *Mesoblast; MesoScale Diagnostics, Inc.; Millennium, the Takeda Oncology Co.; *Miltenyi Biotec, Inc.; Mundipharma EDO; National Marrow Donor Program; Novartis Pharmaceuticals Corporation; PCORI; *Pfizer, Inc; *Pharmacyclics, LLC; PIRCHE AG; *Sanofi Genzyme; *Seattle Genetics; Shire; Spectrum Pharmaceuticals, Inc.; St. Baldrick's Foundation; Swedish Orphan Biovitrum, Inc.; Takeda Oncology; and University of Minnesota (* corporate members).